Heterogeneity of Anticitrullinated Peptide Antibodies and Response to Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis

Benjamin A Fisher, Darren Plant, Karin Lundberg, Peter Charles, Anne Barton, Patrick J Venables, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Karim Raza

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)
10 Downloads (Pure)

Abstract

OBJECTIVE:

To examine fine specificity of anticitrullinated peptide antibodies (ACPA) in relation to responsiveness to anti-tumor necrosis factor (anti-TNF) agents in rheumatoid arthritis (RA).

METHODS:

Samples from 450 patients with RA treated with anti-TNF agents were analyzed for antibodies to citrullinated α-enolase, vimentin, and fibrinogen peptides. The Disease Activity Score-28 was measured at baseline and 6 months.

RESULTS:

Both anti-cFib antibodies and the number of citrullinated peptides recognized were associated with a poorer response. These findings were not significant following stratification for anti-cyclic citrullinated peptide 2 antibodies.

CONCLUSION:

The presence of any ACPA rather than individual ACPA specificities was associated with a poorer response to anti-TNF agents. We suggest that this reflects distinctive differences in the pathogenesis of ACPA-positive and negative RA.
Original languageEnglish
Pages (from-to)929-932
Number of pages4
JournalThe Journal of Rheumatology
Volume39
Issue number5
Early online date1 Apr 2012
DOIs
Publication statusPublished - May 2012

Fingerprint

Dive into the research topics of 'Heterogeneity of Anticitrullinated Peptide Antibodies and Response to Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis'. Together they form a unique fingerprint.

Cite this